Phase 2 Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with relapsing multiple sclerosis (a form of MS where symptoms come and go or worsen in episodes), confirmed using a recognised set of medical guidelines.
- People whose MS-related disability level falls within a certain range, as measured by a standard neurological scoring tool (confirm with trial site).
- People whose MS has been neurologically stable for more than 30 days before the start of the screening process and before the first day of the trial.
- Women who could become pregnant must agree to use an effective form of contraception from the time of agreeing to join, and for 6 months after the last dose of the study drug.
Who may not be able to join:
- People who have a form of MS classified as primary-progressive, or an inactive form of secondary progressive MS.
- People who have another active, long-term condition affecting the immune system (other than MS), or who have an immune deficiency condition.
- People who have significantly reduced bone marrow function, or abnormally low levels of certain blood cells (white blood cells or platelets).
- People who have taken an approved MS medication within a certain period before screening, based on how long that medication stays active in the body (confirm with trial site).
- People who have taken part in another clinical trial and received an experimental treatment within a certain period before screening, based on how long that treatment stays active in the body (confirm with trial site).
- Women who are currently pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-575-8489
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part 2: Area under the curve (AUC) at Steady State [AUCss] of Ublituximab
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.